Angela R Elam1, Chris Andrews1, David C Musch2, Paul P Lee1, Joshua D Stein3. 1. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan; Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan. 2. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan; Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan. 3. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan; Center for Eye Policy and Innovation, University of Michigan, Ann Arbor, Michigan; Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan. Electronic address: jdstein@med.umich.edu.
Abstract
PURPOSE: To determine whether the type of health insurance a patient possesses and a patient's race/ethnicity affect receipt of common tests to monitor open-angle glaucoma (OAG). DESIGN: Retrospective longitudinal cohort study. PARTICIPANTS: A total of 21 766 persons aged ≥40 years with newly diagnosed OAG between 2007 and 2011 enrolled in Medicaid or a large United States managed care network. METHODS: We determined the proportion of patients with newly diagnosed OAG who underwent visual field (VF) testing, fundus photography (FP), other ocular imaging (OOI), or none of these tests within the first 15 months after initial OAG diagnosis. Multivariable logistic regression was used to assess the extent by which health insurance type and race/ethnicity affected the odds of undergoing glaucoma testing. MAIN OUTCOME MEASURES: Odds ratios (OR) of undergoing VF testing, FP, OOI, or none of these tests in the 15 months after initial OAG diagnosis with 95% confidence intervals (CI). RESULTS: A total of 18 372 persons with commercial health insurance and 3394 Medicaid recipients met the study inclusion criteria. The proportions of persons with commercial health insurance with newly diagnosed OAG who underwent VF, FP, and OOI were 63%, 22%, and 54%, respectively, whereas the proportions were 35%, 19%, and 30%, respectively, for Medicaid recipients. Compared with those with commercial health insurance, Medicaid recipients were 234% more likely to not receive any glaucoma testing in the 15 months after initial diagnosis (OR = 3.34; 95% CI, 3.07-3.63). After adjustment for confounders, whites with OAG enrolled in Medicaid had 198% higher odds of receiving no glaucoma testing compared with whites possessing commercial health insurance (OR = 2.98; 95% CI, 2.66-3.33). Blacks with Medicaid insurance demonstrated 291% higher odds (OR = 3.91; 95% CI, 3.40-4.49) of not receiving any glaucoma testing compared with blacks with commercial health insurance. CONCLUSIONS: Irrespective of race/ethnicity, Medicaid recipients with OAG are receiving substantially less glaucoma testing compared with persons with commercial health insurance. Disparities in testing are observed across all races/ethnicities but were most notable for blacks. These findings are particularly disconcerting because blacks are more likely than whites to go blind from OAG and there are disproportionately more blacks in Medicaid. Efforts are needed to improve the quality of glaucoma care for Medicaid recipients, especially racial minorities.
PURPOSE: To determine whether the type of health insurance a patient possesses and a patient's race/ethnicity affect receipt of common tests to monitor open-angle glaucoma (OAG). DESIGN: Retrospective longitudinal cohort study. PARTICIPANTS: A total of 21 766 persons aged ≥40 years with newly diagnosed OAG between 2007 and 2011 enrolled in Medicaid or a large United States managed care network. METHODS: We determined the proportion of patients with newly diagnosed OAG who underwent visual field (VF) testing, fundus photography (FP), other ocular imaging (OOI), or none of these tests within the first 15 months after initial OAG diagnosis. Multivariable logistic regression was used to assess the extent by which health insurance type and race/ethnicity affected the odds of undergoing glaucoma testing. MAIN OUTCOME MEASURES: Odds ratios (OR) of undergoing VF testing, FP, OOI, or none of these tests in the 15 months after initial OAG diagnosis with 95% confidence intervals (CI). RESULTS: A total of 18 372 persons with commercial health insurance and 3394 Medicaid recipients met the study inclusion criteria. The proportions of persons with commercial health insurance with newly diagnosed OAG who underwent VF, FP, and OOI were 63%, 22%, and 54%, respectively, whereas the proportions were 35%, 19%, and 30%, respectively, for Medicaid recipients. Compared with those with commercial health insurance, Medicaid recipients were 234% more likely to not receive any glaucoma testing in the 15 months after initial diagnosis (OR = 3.34; 95% CI, 3.07-3.63). After adjustment for confounders, whites with OAG enrolled in Medicaid had 198% higher odds of receiving no glaucoma testing compared with whites possessing commercial health insurance (OR = 2.98; 95% CI, 2.66-3.33). Blacks with Medicaid insurance demonstrated 291% higher odds (OR = 3.91; 95% CI, 3.40-4.49) of not receiving any glaucoma testing compared with blacks with commercial health insurance. CONCLUSIONS: Irrespective of race/ethnicity, Medicaid recipients with OAG are receiving substantially less glaucoma testing compared with persons with commercial health insurance. Disparities in testing are observed across all races/ethnicities but were most notable for blacks. These findings are particularly disconcerting because blacks are more likely than whites to go blind from OAG and there are disproportionately more blacks in Medicaid. Efforts are needed to improve the quality of glaucoma care for Medicaid recipients, especially racial minorities.
Authors: Joshua D Stein; Denise S Kim; Leslie M Niziol; Nidhi Talwar; Bin Nan; David C Musch; Julia E Richards Journal: Ophthalmology Date: 2011-02-18 Impact factor: 12.079
Authors: Meredith Matone; Russell Localio; Yuan-Shung Huang; Susan dosReis; Chris Feudtner; David Rubin Journal: Health Serv Res Date: 2012-09-04 Impact factor: 3.402
Authors: Bruce E Prum; Lisa F Rosenberg; Steven J Gedde; Steven L Mansberger; Joshua D Stein; Sayoko E Moroi; Leon W Herndon; Michele C Lim; Ruth D Williams Journal: Ophthalmology Date: 2015-11-12 Impact factor: 12.079
Authors: Omar A Halawa; Ajay Kolli; Gahee Oh; William G Mitchell; Robert J Glynn; Dae Hyun Kim; David S Friedman; Nazlee Zebardast Journal: Ophthalmology Date: 2021-10-06 Impact factor: 12.079
Authors: Brent Siesky; Alon Harris; Aditya Belamkar; Ryan Zukerman; Avery Horn; Alice Verticchio Vercellin; Kristen A Mendoza; Paul A Sidoti; Francesco Oddone Journal: J Glaucoma Date: 2022-03-29 Impact factor: 2.290
Authors: Yoon H Lee; Andrew X Chen; Varshini Varadaraj; Gloria H Hong; Yimin Chen; David S Friedman; Joshua D Stein; Nicholas Kourgialis; Joshua R Ehrlich Journal: JAMA Ophthalmol Date: 2018-06-01 Impact factor: 7.389
Authors: Brian Stagg; Eduardo B Mariottoni; Samuel Berchuck; Alessandro Jammal; Angela R Elam; Rachel Hess; Kensaku Kawamoto; Benjamin Haaland; Felipe A Medeiros Journal: Br J Ophthalmol Date: 2021-05-13 Impact factor: 5.908
Authors: Lucas W Rowe; Melanie Scheive; Hanna L Tso; Patrick Wurster; Nicholas E Kalafatis; David A Camp; Avrey Thau; Chi Wah Rudy Yung Journal: BMC Med Educ Date: 2021-12-02 Impact factor: 2.463